Technology Transfer Funding Opportunity: Direct-to-Phase II Award
National Institute of Allergy and Infectious Diseases sent this bulletin at 07/14/2014 02:28 PM EDT
Leading Research to Understand, Treat, and Prevent Infectious, Immunologic, and Allergic Diseases |
    Visit us on the Web |
Technology Transfer Funding Opportunity: Direct-to-Phase II Award
A new funding opportunity announcement (FOA) is available to move commercially viable diagnostic inventions from NIAID and NIDDK intramural research laboratories into the marketplace. This FOA solicits Small Business Innovation Research (SBIR) grant applications from Small Business Concerns (SBCs) for projects that further develop and commercialize such inventions.
The Direct-to-Phase II grant mechanism authorizes participating federal agencies to issue a Phase II award to an SBC that did not receive a Phase I award for that research/research and development. It also allows an SBC to move directly into a Phase II-type research and development that tests the functional viability of the prototype according to scientific methods and potential for commercial development.
Any project that fits within the NIAID and NIDDK mission and relies on the use of the NIAID or NIDDK intramural invention(s) listed in the FOA is eligible for this award.
See FOA: NIAID SBIR – Technology Transfer Direct Phase II (SBIR-TT) (R44) for all the details on eligibility and applying, and see the FAQ page for more information.
Having trouble viewing this email? View it as a Web page.